Dyne Therapeutics Inc. (DYN)
NASDAQ: DYN
· Real-Time Price · USD
11.70
-0.40 (-3.31%)
At close: May 14, 2025, 3:59 PM
12.62
7.91%
Pre-market: May 15, 2025, 04:03 AM EDT
Company Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics Inc.
| Country | United States |
| IPO Date | Sep 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 192 |
| CEO | John G. Cox M.B.A. |
Contact Details
Address: 1560 Trapelo Road Waltham, Massachusetts United States | |
| Website | https://www.dyne-tx.com |
Stock Details
| Ticker Symbol | DYN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818794 |
| CUSIP Number | 26818M108 |
| ISIN Number | US26818M1080 |
| Employer ID | 36-4883909 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John G. Cox M.B.A. | Chief Executive Officer, President & Director |
| Daniel Wilson | Senior Vice President & Head of Legal |
| Debra Feldman | Chief Regulatory Affairs Officer |
| Dr. Ashish Dugar M.B.A., Ph.D. | Chief Medical Affairs Officer |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Innovation Officer |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Officer |
| James P. Bilotta M.B.A. | Chief Digital & Information Officer |
| Johanna Friedl-Naderer | Chief Commercial Officer |
| Lucia Celona | Chief Human Resource Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 08, 2025 | 8-K | Current Report |
| May 08, 2025 | 10-Q | Quarterly Report |
| Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 15, 2025 | ARS | Filing |
| Apr 15, 2025 | DEFA14A | Filing |
| Apr 15, 2025 | DEF 14A | Filing |
| Apr 01, 2025 | 4 | Filing |
| Apr 01, 2025 | 3 | Filing |